Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
These findings suggest that 1 L DRd DoT is a potential predictor of OS when used in Japanese clinical practice.
Authors
- Kazuhito Suzuki (ORCID: https://orcid.org/0000-0002-0300-378X)
- David Bin‐Chia Wu (ORCID: https://orcid.org/0000-0002-0313-5758)
- Yosuke Koroki (ORCID: https://orcid.org/0000-0003-1461-5869)
- Miku Ito (ORCID: https://orcid.org/0000-0001-7773-1360)
- Hiroaki Tsuchiya (ORCID: https://orcid.org/0000-0001-6530-7298)
- Chika Sakai (ORCID: https://orcid.org/0000-0003-3686-6669)
Institutions
- Jikei University School of Medicine (JP)
- Johnson & Johnson (United States) (US)
- National University of Singapore (SG)
- Johnson & Johnson (Singapore) (SG)
- Johnson & Johnson (Sweden) (SE)
- Taylor's University (MY)
- National University Health System (SG)
- Johnson & Johnson (Brazil) (BR)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/03007995.2025.2590840
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00